Impact of the oncology care model on use of supportive care medications during cancer treatment

According to results from a recent study, the Oncology Care Model—an alternative cancer care payment model for reducing Medicare spending—was associated with a relative reduction in the use of denosumab for beneficiaries with bone metastases from breast, lung, or prostate cancer receiving bone-modifying medications.